Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22242662 | 1.00 | KMT2A (0.59) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL2875215 | 1.00 | KMT2A (0.59) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL8939993 | 0.88 | ALDH1A1 (0.64) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL1415776 | 0.86 | KMT2A (0.56) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL5641347 | 0.85 | MAPK1 (0.56) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL17275434 | 0.85 | MAPK1 (0.56) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL17595505 | 0.85 | MAPK1 (0.59) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL5798482 | 0.83 | MAPK1 (0.58) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL5798484 | 0.83 | MAPK1 (0.58) | KMT2AMAPK1ALDH1A1MAPTRAB9A | |
| SCHEMBL30268729 | 0.83 | MAPK1 (0.58) | KMT2AMAPK1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184477-A | Method for preparing chiral amino alcohol compound by catalyzing amino ketone with nickel metal by using water as hydrogen source | 云南民族大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | disclosed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | disclosed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-8158827-B2 | Transfection reagents | Life Technologies Corporation (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158827-B2 | Transfection reagents | Life Technologies Corporation (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2298728-A1 | Transfection reagents | Life Technologies Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| US-20090143583-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143583-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
| EP-1829856-A2 | Transfection reagents | INVITROGEN CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143583-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | KMT2A 1515/4885MAPK1 4469/4885ALDH1A1 3974/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | KMT2A 3784/4885MAPK1 2345/4885ALDH1A1 241/4885 |
| US-20130045955-A1 | NOVEL COMPOUNDS | ABCG2, F12, CFTR | KMT2A 3922/4885MAPK1 3398/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.